EARLY RESPONSE TO CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS PREDICTS OUTCOME AT ONE YEAR

被引：0
|
作者：
Berenbaum, F. [1 ]
Pham, T. [2 ]
Fautrel, B. [3 ]
Joubert, J. M. [4 ]
De Chalus, T. [4 ]
Franca, Riou L. [5 ]
Claudepierre, P. [6 ]
机构：
[1] CHU St Antoine, Paris, France
[2] CHU St Marguerite, Marseille, France
[3] CHU Pitie Salpetriere, Paris, France
[4] UCB Pharma, Colombes, France
[5] Phisquare Inst, Paris, France
[6] Grp Hosp Henri Mondor, Creteil, France
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1452
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A556 / A556
页数：1
相关论文
共 50 条
  • [41] CLINICAL EFFECTIVENESS OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A MULTICENTRE STUDY
    Isaacs, Anthony
    Abraham, Sonya
    RHEUMATOLOGY, 2014, 53 : 109 - 109
  • [42] Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Florenzo Iannone
    Angelo Semeraro
    Giorgio Carlino
    Leonardo Santo
    Romano Bucci
    Laura Quarta
    Nicola Maruotti
    Carmelo Zuccaro
    Antonio Marsico
    Paola Chiara Francesca Falappone
    Daniela Mazzotta
    Francesco Paolo Cantatore
    Maurizio Muratore
    Giovanni Lapadula
    Clinical Drug Investigation, 2019, 39 : 565 - 575
  • [43] Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Iannone, Florenzo
    Semeraro, Angelo
    Carlino, Giorgio
    Santo, Leonardo
    Bucci, Romano
    Quarta, Laura
    Maruotti, Nicola
    Zuccaro, Carmelo
    Marsico, Antonio
    Falappone, Paola Chiara Francesca
    Mazzotta, Daniela
    Cantatore, Francesco Paolo
    Muratore, Maurizio
    Lapadula, Giovanni
    CLINICAL DRUG INVESTIGATION, 2019, 39 (06) : 565 - 575
  • [44] Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis
    Morita, Takayoshi
    Fujimoto, Kosuke
    Shima, Yoshihito
    Ogata, Atsushi
    Kumanogoh, Atsushi
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (09)
  • [45] EFFICACY OF THE INITIAL TREATMENT WITH CERTOLIZUMAB PEGOL FOR RHEUMATOID ARTHRITIS: A MULTICENTER STUDY
    Hattori, Y.
    Kaneko, A.
    Kida, D.
    Kanayama, Y.
    Hirano, Y.
    Kanda, H.
    Kojima, T.
    Ishiguro, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 473 - 473
  • [46] DELAYED CUTANEOUS HYPERSENSITIVITY REACTION TO CERTOLIZUMAB PEGOL IN A PATIENT WITH RHEUMATOID ARTHRITIS
    Iammatteo, M.
    Lowes, M.
    Broder, A.
    Jovanovic, B.
    Sarwar, U.
    Jacobson, M.
    Jerschow, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A46 - A47
  • [47] Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
    Furst, D. E.
    Shaikh, S. A.
    Greenwald, M.
    Bennett, B.
    Davies, O.
    Luijtens, K.
    Staelens, F.
    Koetse, W.
    Bertin, P.
    ARTHRITIS CARE & RESEARCH, 2015, 67 (02) : 151 - 160
  • [48] Certolizumab Pegol: in rheumatoid arthritis (vol 23, pg 407, 2009)
    Duggan, S. T.
    Keam, S. J.
    BIODRUGS, 2010, 24 (01) : 54 - 54
  • [49] Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
    Aletaha, Daniel
    Funovits, Julia
    Keystone, Edward C.
    Smolen, Josef S.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (10): : 3226 - 3235
  • [50] Predicting Future Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Features at 12 Weeks Associated With Low Disease Activity at 1 Year
    Curtis, Jeffrey R.
    Luijtens, Kristel
    Kavanaugh, Arthur
    ARTHRITIS CARE & RESEARCH, 2012, 64 (05) : 658 - 667
12345